Recherche
-
Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)
(Frontiers in Pharmacology. vol. 12, pp. 682890, 2021-11-03)Article de revueLibre accès -
Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe
(Pharmacoepidemiology and Drug Safety, 2021-06-28)Article de revueLibre accès -
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database
(Atherosclerosis. vol. 281, pp. 98-106, 2019)Article de revue -
Treatment resistant depression incidence and prevalence using the French nationwide claims database
(Pharmacoepidemiology and Drug Safety. vol. 30, n° 2, pp. 169–177, 2021-02)Article de revue -
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
(British Journal of Clinical Pharmacology. vol. 85, n° 2, pp. 432-441, 2019)Article de revue -
Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study
(Pharmacoepidemiology and drug safety. vol. 27, n° 11, pp. 1174-1181, 2018-11)Article de revue -
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation
(Stroke. vol. 50, n° 9, pp. 2469-2476, 2019)Article de revueLibre accès -
Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data
(BMC Medical Research Methodology. vol. 21, n° 1, pp. 95, 2021-05-01)Article de revueLibre accès -
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation
(Clinical Pharmacology and Therapeutics. vol. 105, n° 6, pp. 1439-1455, 2019)Article de revue -
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
(American Journal of Cardiovascular Drugs, 2021-12-21)Article de revue